Cargando…

Repurposing anthelmintic agents to eradicate resistant leukemia

Despite rapid progress in genomic profiling in acute lymphoblastic leukemia (ALL), identification of actionable targets and prediction of response to drugs remains challenging. To identify specific vulnerabilities in ALL, we performed a drug screen using primary human ALL samples cultured in a model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mezzatesta, Caterina, Abduli, Liridon, Guinot, Anna, Eckert, Cornelia, Schewe, Denis, Zaliova, Marketa, Vinti, Luciana, Marovca, Blerim, Tsai, Yi-Chien, Jenni, Silvia, Aguade-Gorgorio, Julia, von Stackelberg, Arend, Schrappe, Martin, Locatelli, Franco, Stanulla, Martin, Cario, Gunnar, Bourquin, Jean-Pierre, Bornhauser, Beat C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320149/ https://www.ncbi.nlm.nih.gov/pubmed/32591499 http://dx.doi.org/10.1038/s41408-020-0339-9

Ejemplares similares

Image-based RNA interference screening reveals an individual dependence of acute lymphoblastic leukemia on stromal cysteine support
por: Boutter, Jeannette, et al.
Publicado: (2014)

Frequency and prognostic impact of ZEB2 H1038 and Q1072 mutations in childhood B-other acute lymphoblastic leukemia
por: Zaliova, Marketa, et al.
Publicado: (2020)

Rapid Generation of Leukemogenic Chromosomal Translocations in Vivo Using CRISPR/Cas9
por: Huang, Yun, et al.
Publicado: (2020)

PDX models recapitulate the genetic and epigenetic landscape of pediatric T‐cell leukemia
por: Richter‐Pechańska, Paulina, et al.
Publicado: (2018)

Molecular complete remission following combination treatment of daratumumab and venetoclax in an adolescent with relapsed mixed phenotype acute leukemia
por: Stanulla, Martin, et al.
Publicado: (2023)

The Clinical Utility of Optical Genome Mapping for the Assessment of Genomic Aberrations in Acute Lymphoblastic Leukemia
por: Lühmann, Jonathan Lukas, et al.
Publicado: (2021)

Adaptive dynamics of unstable cancer populations: The canonical equation
por: Aguadé‐Gorgorió, Guim, et al.
Publicado: (2018)

Genetic instability as a driver for immune surveillance
por: Aguadé-Gorgorió, Guim, et al.
Publicado: (2019)

LRH‐1/NR5A2 interacts with the glucocorticoid receptor to regulate glucocorticoid resistance
por: Michalek, Svenja, et al.
Publicado: (2022)

Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity
por: Aguadé-Gorgorió, Guim, et al.
Publicado: (2021)

P330: PROTEOMIC PROFILING UNCOVERS THERAPEUTIC VULNERABILITIES FOR TCF3 TRANSLOCATED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIAS
por: Hasselmann, Rebecca, et al.
Publicado: (2023)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis
por: Vogiatzi, Fotini, et al.
Publicado: (2022)

P322: DECIPHERING THE UNDERLYING MOLECULAR COMPLEXITY OF THE IKZF1PLUS SIGNATURE
por: Lühmann, Jonathan, et al.
Publicado: (2023)

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
por: Möricke, Anja, et al.
Publicado: (2023)

Tumor necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study of patients treated with BFM therapy
por: Stanulla, Martin, et al.
Publicado: (2001)

Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population
por: Schnakenberg, Eckart, et al.
Publicado: (2005)

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols
por: Cario, Gunnar, et al.
Publicado: (2020)

Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
por: Mezzatesta, Caterina, et al.
Publicado: (2019)

Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved Diagnostics
por: Chouvarine, Philippe, et al.
Publicado: (2021)

P333: SUBCLONAL AND CLONAL VARIANTS IN TP53 AND KRAS COMBINED WITH POOR TREATMENT RESPONSE IDENTIFY A SUBGROUP OF ULTRA-HIGH-RISK PATIENTS OF PEDIATRIC T-LYMPHOBLASTIC LEUKEMIA (T-ALL)
por: Kempter, Tamara, et al.
Publicado: (2023)

Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia
por: Palmi, Chiara, et al.
Publicado: (2023)

Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution
por: Richter-Pechańska, Paulina, et al.
Publicado: (2022)

Anthelmintics for drug repurposing: Opportunities and challenges
por: Alavi, Seyed Ebrahim, et al.
Publicado: (2021)

Chromatin accessibility landscape of pediatric T‐lymphoblastic leukemia and human T‐cell precursors
por: Erarslan‐Uysal, Büşra, et al.
Publicado: (2020)

B- and T-cell acute lymphoblastic leukemias evade chemotherapy at distinct sites in the bone marrow
por: Barz, Malwine J., et al.
Publicado: (2022)

Where are all the anthelmintics? Challenges and opportunities on the path to new anthelmintics
por: Nixon, Samantha A., et al.
Publicado: (2020)

The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
por: Son, Deok-Soo, et al.
Publicado: (2020)

Repurposing of Benzimidazole Anthelmintic Drugs as Cancer Therapeutics
por: Song, Bomi, et al.
Publicado: (2022)

Frequency and prognostic impact of PAX5 p.P80R in pediatric acute lymphoblastic leukemia patients treated on an AIEOP‐BFM acute lymphoblastic leukemia protocol
por: Jung, Mareike, et al.
Publicado: (2020)

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia
por: Kellner, Christian, et al.
Publicado: (2018)

On Anthelmintics
Publicado: (1875)

Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL
por: Antić, Željko, et al.
Publicado: (2023)

Anthelmintics – From Discovery to Resistance
por: Wolstenholme, Adrian J., et al.
Publicado: (2014)

Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study
por: Kidas, Ekaterini, et al.
Publicado: (2009)

KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia
por: Malinowska-Ozdowy, K, et al.
Publicado: (2015)

Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori
por: Tharmalingam, Nagendran, et al.
Publicado: (2018)

BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy
por: Cario, Gunnar, et al.
Publicado: (2020)

Targeting subtype in ALL
por: von Stackelberg, Arend
Publicado: (2019)

Anthelmintics V: Drugs, resistance, and vaccines
por: Aroian, Raffi V., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3asr8al3t19eflcqf3hjnrqtp2